Indacaterol therapy in moderate-to-severe chronic obstructive pulmonary disease: findings from a single-center primary care cohort

Indacaterol therapy in moderate-to-severe chronic obstructive pulmonary disease: findings from a single-center primary care cohort

Mukesh P SinghHorsefair Practice Group, Sandy Lane Health Centre, Rugeley, UKBackground: Once-daily long-acting β2-agonists (LABAs) are an important treatment option, either alone or in combination with other inhaled long-acting bronchodilators in the management of chronic obstructive pulmo...

Full description

Bibliographic Details
Main Author:	Singh MP
Format:	Article
Language:	English
Published:	Dove Medical Press 2013-12-01
Series:	International Journal of COPD
Online Access:	http://www.dovepress.com/nbspindacaterol-therapy-in-moderate-to-severe-chronic-obstructive-pulm-a15229

Similar Items

Indacaterol for chronic obstructive pulmonary disease: systematic review and meta-analysis.
by: Vincent C H Chung, et al.
Published: (2013-01-01)

Comparative Effectiveness of Umeclidinium/Vilanterol versus Indacaterol/Glycopyrronium on Moderate-to-Severe Exacerbations in Patients with Chronic Obstructive Pulmonary Disease in Clinical Practice in England
by: Requena G, et al.
Published: (2023-09-01)

Improving the quality of life in patients with chronic obstructive pulmonary disease: focus on indacaterol
by: Feldman GJ
Published: (2013-02-01)

Indacaterol improves daily physical activity in patients with chronic obstructive pulmonary disease
by: Hataji O, et al.
Published: (2012-12-01)

Influence of indacaterol on daily physical activity in patients with untreated chronic obstructive pulmonary disease
by: Nishijima Y, et al.
Published: (2015-02-01)

Direct Switch from Tiotropium to Indacaterol/Glycopyrronium in Chronic Obstructive Pulmonary Disease Patients in Korea
by: Sang Haak Lee, et al.
Published: (2021-04-01)

Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol
by: Roskell NS, et al.
Published: (2014-07-01)

Budget impact model of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease in Italy based on the FLAME study
by: Andrea Aiello, et al.
Published: (2018-10-01)

Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches
by: Lawrence David, et al.
Published: (2011-04-01)

Indacaterol 75 µg once daily for the treatment of patients with chronic obstructive pulmonary disease: a North American perspective
by: Edward M. Kerwin, et al.
Published: (2013-02-01)

Effects of indacaterol versus tiotropium on respiratory mechanics assessed by the forced oscillation technique in patients with chronic obstructive pulmonary disease
by: Inui N, et al.
Published: (2015-06-01)

The lung microbiome in moderate and severe chronic obstructive pulmonary disease.
by: Alexa A Pragman, et al.
Published: (2012-01-01)

Profiling the bronchodilator effects of the novel ultra-long-acting β-agonist indacaterol against established treatments in chronic obstructive pulmonary disease
by: Claus Vogelmeier, et al.
Published: (2011-10-01)

Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US
by: Rajagopalan K, et al.
Published: (2018-11-01)

INFLOW study: a prospective observational study for assessment of indacaterol and other bronchodilators in symptomatic chronic obstructive pulmonary disease patients from Egypt
by: Waleed M. El-Sorougi, et al.
Published: (2017-01-01)

Effect of doxycycline in patients of moderate to severe chronic obstructive pulmonary disease with stable symptoms
by: Prashant S Dalvi, et al.
Published: (2011-01-01)

Comparing Clinical Outcomes of Tiotropium/Olodaterol, Umeclidinium/Vilanterol, and Indacaterol/Glycopyrronium Fixed-Dose Combination Therapy in Patients with Chronic Obstructive Pulmonary Disease in Taiwan: A Multicenter Cohort Study
by: Hsieh MJ, et al.
Published: (2022-04-01)

Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada
by: Mtibaa M, et al.
Published: (2021-12-01)

The Burden of Illness in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease in Canada
by: M Reza Maleki-Yazdi, et al.
Published: (2012-01-01)

Effects of combination therapy indacaterol/glycopyrronium versus tiotropium on moderate to severe COPD: evaluation of impulse oscillometry and exacerbation rate
by: Antonio Molino, et al.
Published: (2017-09-01)

An update on the use of indacaterol in patients with COPD
by: Nadia S. Brienza, et al.
Published: (2011-02-01)

Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease
by: James Donohue, et al.
Published: (2019-10-01)

A randomized trial to determine the impact of indacaterol/glycopyrronium on nighttime oxygenation and symptoms in patients with moderate-to-severe COPD: the DuoSleep study
by: Lehmann S, et al.
Published: (2019-01-01)

Inhaled indacaterol for the treatment of COPD patients with destroyed lung by tuberculosis and moderate-to-severe airflow limitation: results from the randomized INFINITY study
by: Kim CJ, et al.
Published: (2017-05-01)

Efficacy of indacaterol on quality of life and pulmonary function in patients with COPD and inhaler device preferences
by: Ohno T, et al.
Published: (2014-01-01)

Effects of modified pulmonary rehabilitation on patients with moderate to severe chronic obstructive pulmonary disease: A randomized controlled trail
by: Jingjuan Xu, et al.
Published: (2017-07-01)

Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study
by: Vincken W, et al.
Published: (2014-02-01)

Indacaterol: A novel, Inhaled Beta-2 agonist for COPD
by: Ved Prakash, et al.
Published: (2015-01-01)

Role of Low-Dose Theophylline on Functional Improvement in Patients of Moderately Severe Chronic Obstructive Pulmonary Disease
by: Muhammad Umer Farooq, et al.
Published: (2023-03-01)

Cost-Effectiveness Analysis of Triple Combination Preparations in the Treatment of Moderate-to-Severe Chronic Obstructive Pulmonary Disease
by: Yikang Zhou, et al.
Published: (2021-07-01)

Quadriceps bulk and strength and effect of its training in patients with moderate to severe chronic obstructive pulmonary disease
by: Nasr Affara, et al.
Published: (2013-01-01)

The role of pharmacotherapy in mild to moderate chronic obstructive pulmonary disease
by: Natya Raghavan, et al.
Published: (2011-08-01)

Office-Based Case Finding for Chronic Obstructive Pulmonary Disease in Older Adults in Primary Care
by: Linda Lee, et al.
Published: (2016-01-01)

Prognostic risk factors for moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease: a systematic literature review
by: John R. Hurst, et al.
Published: (2022-08-01)

Clinical Characteristics of Non-Smoking Chronic Obstructive Pulmonary Disease Patients: Findings from the KOCOSS Cohort
by: Joon Young Choi, et al.
Published: (2022-12-01)

Clinical Characteristics of Chronic Obstructive Pulmonary Disease in Female Patients: Findings from a KOCOSS Cohort
by: Choi JY, et al.
Published: (2020-09-01)

Supported self-management for patients with moderate to severe chronic obstructive pulmonary disease (COPD): an evidence synthesis and economic analysis
by: Rachel E Jordan, et al.
Published: (2015-05-01)

Spirometry in primary care for case finding and management of chronic obstructive pulmonary disease primary care diagnostic technology update.
by: Parkes, G, et al.
Published: (2011)

Effects of indacaterol versus tiotropium on exercise tolerance in patients with moderate COPD: a pilot randomized crossover study
by: Danilo Cortozi Berton, et al.

Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial
by: Claus F. Vogelmeier, et al.
Published: (2017-07-01)